Saxagliptin 5 mg

DRUG4 trials

Sponsors

Merck Sharp & Dohme LLC, AstraZeneca

Conditions

Type 2 Diabetes MellitusType 2 Diabetes Mellitus(T2DM)

Phase 1

A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)

CompletedNCT01582308

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2012-06-21End: 2012-12-14Updated: 2017-05-30

A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration

CompletedNCT01755494

AstraZenecaType 2 Diabetes Mellitus(T2DM)

Start: 2013-02-28End: 2013-04-30Updated: 2013-12-13

Phase 3

Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control

CompletedNCT02273050

AstraZenecaType 2 Diabetes Mellitus

Start: 2014-12-31End: 2016-08-31Updated: 2018-02-05

Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin

TerminatedNCT03608358

AstraZenecaType 2 Diabetes Mellitus

Start: 2019-02-27End: 2020-08-04Updated: 2022-05-31

Related Papers

Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: Results from the START study, a multicentre, randomized, double-blind, active-controlled, phase 3 trial.

2017-10-2619 citations